Loading...
•
Mar 31, 2020
Pacira Q1 2020 Earnings Report
Pacira BioSciences reported an increase in total revenues and a shift to net income in Q1 2020.
Key Takeaways
Pacira BioSciences reported a 16% increase in total revenues to $105.7 million for the first quarter of 2020, driven by growth in EXPAREL net product sales. The company achieved GAAP net income of $8.2 million, or $0.19 per share, compared to a net loss in the prior year. Due to the COVID-19 pandemic, the company has withdrawn its full-year 2020 financial guidance.
Total revenues increased by 16% to $105.7 million compared to Q1 2019.
EXPAREL net product sales grew by 12% to $101.3 million.
GAAP net income was $8.2 million, or $0.19 per share, a significant improvement from the net loss in Q1 2019.
The company ended the quarter with $353.6 million in cash, cash equivalents, and investments.
Revenue by Segment
Forward Guidance
Due to the rapidly changing variables related to the COVID-19 pandemic, the company does not have sufficient visibility to accurately forecast the impact of this pandemic and, consequently, is temporarily withdrawing all full-year 2020 financial guidance. The company believes expense reductions resulting from COVID-19 will partially mitigate the negative revenue impact of the pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...